| INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are glucoselowering agents recommended for the treatment of type 2 diabetes that have been shown to lower glycated haemoglobin (HbA1c) levels and body weight effectively, and are associated with a low risk of hypoglycaemia and improved systolic blood pressure. [1] [2] [3] [4] Despite these benefits, GLP-1RAs appear to be used less frequently than other new glucose-lowering agents, such as dipeptidyl peptidase-4 inhibitors. 5 An oral GLP-1RA formulation may improve acceptance and adherence 6 for some patients compared with injectable GLP-1RAs
and may lead to earlier initiation of GLP-1RA treatment in type 2 diabetes. However, successful delivery of peptides, such as GLP-1RAs, through the oral route is challenging, because of numerous barriers to absorption, including degradation by gastrointestinal enzymes, pHinduced conformational changes and limited protein permeability of the intestinal membrane. 7, 8 Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue shown to improve glycaemic control and reduce body weight when administered subcutaneously (s.c.) in patients with type 2 diabetes [9] [10] [11] and recently approved for use in Europe, 12 Canada, 13 Japan 14 and the United States, 15 is being developed as a once-daily oral tablet formulation. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that promotes the absorption of semaglutide across the gastric mucosa via effects on transcellular pathways. 16 An oral formulation of semaglutide with similar efficacy and safety to the s.c. formulation has the potential to increase the access of GLP-1 therapies to patients with a preference for oral administration. In a 26-week, phase II trial conducted in 632 patients with type 2 diabetes and sub-optimal glycaemic control, oral semaglutide (doses ranging from 2.5 to 40 mg once daily) reduced HbA1c levels compared with placebo in a dose-dependent manner (−0.7% to −1.9% compared with −0.3% with placebo). 17 In the same trial, oral semaglutide also demonstrated dose-dependent weight reduction (−2.1 to −6.9 kg vs. −1.2 kg with placebo). 17 The phase II study also compared oral semaglutide with s.c. semaglutide 1 mg, with similar reductions in HbA1c and comparable tolerability observed with higher doses of oral semaglutide versus s.c. semaglutide. 17 Based on a combined evaluation of the efficacy and tolerability data in the phase II trial, three doses of oral semaglutide (3, 7 and 14 mg once daily) were selected for evaluation in the PIONEER (Peptide InnOvatioN for Early DiabEtes TReatment) phase IIIa programme, which is ongoing to further investigate the efficacy and safety of oral semaglutide in a large and broad population of patients with type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death in patients with type 2 diabetes. 18 Guidelines have been issued by regulatory authorities to the pharmaceutical industry regarding the evaluation of cardiovascular (CV) safety to exclude an excess in CV risk with new therapies to treat type 2 diabetes. [19] [20] [21] In previous CV outcomes trials, treatment with both s.c. liraglutide and s.c. semaglutide has shown a CVD risk reduction compared with placebo in patients with type 2 diabetes and high CV risk, 22, 23 with some guidelines recommending liraglutide for second-line use after metformin in these patients. 1 As part of the PIONEER programme, and in accordance with regulatory guidance, PIONEER 6 is a pre-approval CV outcomes trial that is being conducted to specifically explore CV safety of oral semaglutide compared with placebo. In the present paper, we describe the design of the PIONEER 6 trial and report the baseline characteristics of the trial population. Approval by relevant local independent ethics committees and institutional review boards, and national regulatory authorities was mandated prior to the commencement of the trial at each site. All patients provided written informed consent prior to any trial-related activity.
A panel of lead principal investigators and selected trial coordinators was nominated to provide advice on the conduct of the trial to the sponsor. An independent data monitoring committee provides an ongoing review of accumulating data and subsequent guidance on trial continuation.
| Participants
Male and female patients diagnosed with type 2 diabetes were eligible for inclusion in the trial if they were considered at high risk of CV 
| Trial treatment and procedures
Eligible patients were randomized in a 1:1 ratio to once-daily treatment with either oral semaglutide or placebo ( Figure 1) , with randomization stratified based on evidence of established CVD/moderate CKD at screening or CV risk factors only. Randomization could occur on the same day as the screening visit or up to 3 weeks afterwards.
Randomization was performed using an interactive voice/web response system (IV/WRS) and blinding of trial staff is maintained by using the same IV/WRS for dispensing of trial drug and through the use of visually identical oral semaglutide and placebo tablets in identical packaging.
The dose for the evaluation of the CV safety of oral semaglutide was 14 mg, which is the maximum dose chosen for study in the PIO-NEER programme. To mitigate the potential for adverse gastrointestinal events, patients followed a dose-escalation regimen receiving 3 mg oral semaglutide/placebo once daily for 4 weeks, followed by 7 mg oral semaglutide/placebo once daily for 4 weeks, and then 14 mg oral semaglutide/placebo once daily for the remainder of the trial ( Figure 1 ). Extensions of the dose-escalation period, dose reductions (and subsequent re-escalation) and treatment pauses (and subsequent re-initiation) were permitted during the trial if, based on the investigator's opinion, unacceptable adverse events (AEs) occurred.
Patients were instructed to take the tablet in the morning in a fasting state with up to half a glass of water (approximately 120 mL) and to wait at least 30 minutes before eating, drinking or taking other oral concomitant medication.
The study flow and visit schedule is presented in Figure 1 and Supplementary Table 1 
| Endpoints and assessments
The primary endpoint is time from randomization to first occurrence 
| Trial duration and follow-up
PIONEER 6 is an event-driven trial and will continue until at least 122 adjudication-confirmed first MACEs have occurred. There is no pre-specified duration of exposure to trial medication and so it is likely that there will be fewer primary endpoint events than seen in the similar CV outcome trials for liraglutide and s.c. semaglutide. 22, 23 Followup visits will be held 5 weeks after the end-of-treatment visit to allow safety assessments after wash-out of the trial drug. Patients who discontinue trial drug prematurely will continue to be followed in accordance with the planned visit schedule. No interim analyses are planned, other than those conducted by an independent data monitoring committee.
| Statistical methods
The trial aims to confirm that treatment with oral semaglutide does not result in an unacceptable increase in CV risk compared with pla- Analysis of the primary endpoint (time from randomization to first MACE) will include all of the first MACEs occurring during the trial from randomization to the patient's last visit (at follow-up approximately 5 weeks after the last planned dose of the trial product), regardless of adherence to trial treatment and procedures or adjustment of background medication. A stratified Cox proportional hazards model will be used for the primary analysis, with treatment group as a fixed factor, and stratification based on evidence of CVD or advanced CKD at screening. Estimated hazard ratio and the two-sided 95% CI will be determined, with non-inferiority confirmed in accordance with FDA guidance, as outlined earlier. 21 If non-inferiority is confirmed, a test for superiority versus placebo will be performed, thereby preserving the type 1 error in the strong sense at 5% (two-sided) when using the hierarchical testing strategy. Sensitivity analyses will explore the robustness of the primary analysis. All primary and secondary analyses will be performed on the full analysis set, which will include all FIGURE 1 Trial design. MACE, major adverse cardiovascular event randomized patients. According to the study protocol, no interim analyses are planned before the database is locked.
| Sample size
A log-rank test determined that to confirm non-inferiority for the pri- 
| RESULTS
The first patient was randomized on 17th January 2017 and recruitment was completed on 29th August 2017, representing a recruitment period of just over 7 months. In total, 3418 patients underwent screening, with 3183 randomized to treatment. The majority of patients (84.6%) were aged ≥50 years and had established CVD or moderate CKD, while the remainder (15.4%) were aged ≥60 years with the presence of CV risk factors only.
The baseline characteristics of the enrolled patients were compiled in a blinded manner after completion of enrolment and before data cleaning. One third of the randomized patients were female (31.6%) and the mean age at baseline was 66.1 years ( The mechanism whereby GLP-1RAs may reduce CV risk is not fully elucidated. Preclinical studies suggest various potential mechanisms for the CV benefit of these agents. 37 in vitro studies suggest these agents may have effects on adhesion molecules and endothelial function that may inhibit atherosclerosis and thrombosis. 38 Similarly to SUSTAIN 6, the majority (>80%) of patients recruited in PIONEER 6 had prior CVD/moderate CKD, with less than one sixth of participants having only CV risk factors (Table 2) . Moreover, the presence of CV risk factors and use of CV medications was similar in PIO-NEER 6 compared with SUSTAIN 6 (Table S2) . Compared with SUSTAIN 6, PIONEER 6 included a greater proportion of patients receiving SGLT-2 inhibitors (0.2% vs. 9.5%), 23 reflecting the increasing use of this drug class. In contrast to SUSTAIN 6, 23 there was no lower threshold for HbA1c in PIONEER 6, which could explain why baseline HbA1c was lower (66 mmol/mol [8.2%]) than in the LEADER and SUSTAIN 6 studies (72 mmol/mol [8.7%] for both).
22,23
The populations of PIONEER 6 and SUSTAIN 6 23 are very similar to that used in LEADER, 22 but differ from that studied in the ELIXA CV outcomes trial with once-daily s.c. lixisenatide, which included only patients with type 2 diabetes and acute coronary syndrome within the previous 180 days (Table 2) . 27 The EXSCEL CV outcomes trial with once-weekly exenatide included a patient population with a slightly wider range of CV risk, with~73% of the population having prior CVD. 28, 31 As opposed to the other GLP-1RA trials, the ongoing 6 ) and a longer trial duration (7-8 years). 33 The differences in patient populations and trial design from various GLP-1RA CV outcomes trials indicate that care should be taken when comparing outcomes between trials or generalizing data to a broader diabetes population.
Time from randomization to the three-point MACE composite endpoint (CV death, non-fatal MI or non-fatal stroke) was selected as the primary endpoint of PIONEER 6, an approach that captures the three CV events mandated by the FDA for such trials 21 and is consistent with most recent CV outcomes trials with GLP-1RAs ( Table 2) . 19 Although PIONEER 6 has recruited a similar high CV risk patient population to those included in other recent CV outcomes trials in diabetes and includes a similar primary endpoint, differences in trial design will influence interpretation of the final data. PIONEER 6 is powered as a non-inferiority trial to exclude an unacceptable increase in CV risk compared with placebo, as set by the FDA (upper limit of the 95% CI below 1.8). PIONEER 6 is solely event-driven (close down of the trial will be initiated once the estimated number of first MACEs [n = 122] needed to rule out an excess risk have been accrued) and does not include a minimum trial duration. PIONEER 6 will therefore accrue substantially fewer CV events and have a shorter treatment duration than other diabetes treatment CV outcomes trials, such as SUSTAIN 6 and LEADER, which had a minimum trial duration after the last patient was randomized (the median observation time in SUSTAIN 6 and LEADER was 2.1 and 3.8 years respectively [ Table 2 ]). 19, 22, 23 In both the LEADER and SUSTAIN 6 trials, more endpoint events were accrued (approximately double) than the number needed to achieve statistical power, 22, 23 as a result of the minimum duration and higher than expected event rates. The accrual of more events in SUSTAIN 6 allowed that trial to identify a significantly lower risk of the primary outcome (albeit not pre-specified before trial initiation) of three-point MACE among patients treated with s.c. semaglutide compared with placebo (P = 0.02 for superiority of s.c. semaglutide). 23 It has been suggested that trial duration is a factor in being able to demonstrate CV risk reductions in diabetes CV outcomes trials. 39 Nevertheless, a relatively short trial duration was used for PIONEER 6 to allow the CV safety of oral semaglutide to be determined early in the development programme and because the CV safety of semaglutide as a s.c. formulation had already been demonstrated in SUSTAIN 6; however, due to the short duration and expected accrual of fewer events than SUSTAIN 6, a statistically significant CV risk reduction with oral semaglutide versus placebo may be less likely.
| CONCLUSION
In summary, PIONEER 6 is a pre-approval non-inferiority trial that will investigate the CV safety of oral semaglutide compared with placebo and will, therefore, provide an important insight for regulatory approval. The trial has completed enrolment of 3183 patients with 
